

Virus Name: Japanese Encephalitis		Abbreviation: JBEV	
Status Arbovirus	Select Agent No	SALS Level 3	
SALS Basis Results of SALS surveys and information from the Catalogue.			
Other Information DOC Permit Required, USDA High Consequence Agent			
Antigenic Group B			

SECTION I - Full Virus Name and Prototype Number

Prototype Strain Number / Designation Nakayama	Accession Number	Original Date Submitted 8/3/1984
Family Flavivirus	Genus	
Information From Akira Oya and W.F. Scherer	Address National Institutes of Health, Tokyo, and Cornell University Medical College, N.Y.	
Information Footnote Revised		

Section II - Original Source

Isolated By (name) T. Mitamura and M. Kitaoka, et al.	Isolated at Institute Tokyo, Japan	
Host Genus Man	Species	Host Age/Stage 19 years
Sex Male		
<u>Isolated From</u>	<u>Isolation Details</u>	
Organs/Tissues	Brain	
Signs and Symptoms of Illness encephalitis	Arthropod	
Time Held Alive before Inoculation		
Collection Method autopsy	Collection Date 8/21/1935	
Place Collected (Minimum of City, State, Country) hospital in Tokyo		
Latitude 35° N	Longitude 140° E	
Macrohabitat urban	Microhabitat	Method of Storage until Inoculated no storage
Footnotes		

Section III - Method of Isolation

Inoculation Date
8/21/1935

Animal (Details will be in Section 6)
wn mice

Route Inoculated
intracerebral

Reisolation
Yes

Other Reasons

Homologous Antibody Formation by Source Animal
No

Test(s) Used
NT, day 4 serum tested

Footnotes

Section IV - Virus Properties

Physicochemical
RNA, Single Strand

Pieces (number of genome segments)
one

Infectivity
yes

Sedimentation Coefficients
(s)
(S)

Percentage wt, of Virion Protein

Lipid

Carbohydrate

Virion Polypeptides: Number
3

Details
9,000-10,000 MW (membrane polypeptide), 13,000-15,000 MW (capsid polypeptide), 55,000-59,000 MW (spike, glycoprotein, hemagglutinin) (35, 36)

Non-virion Polypeptides: Number
5

Details
10,500, 19,000, 45,000, 71,000, 93,000 MW (36)

Virion Density
1.19 gm/cm³ (35) in sucrose

Sedimentation Coefficients(s)
200S (36)(S)

Nucleocapsid Density
1.31 (36) in sucrose

Sedimentation Coefficients(s)
(S)

Stability of Infectivity (effects)

pH (infective range)

Lipid Solvent (ether - % used to test)
inactivated (3)

After Treatment Titer

Control Titer

Lipid Solvent (chloroform)

After Treatment Titer

Control Titer

Lipid Solvent (deoxycholate)
inactivated (26)

After Treatment Titer

Control Titer

Other (formalin, radiation)
inactivated by urea (29)

Virion Morphology

Shape
spherical

Dimensions
53.1 +/- 4.5 nm

Mean
nm

Range
nm

Measurement Method electron microscopy	Surface Projections/Envelope spikes, 10 nm in length; diameter of envelope = 44.8 +- 3.2 nm (35)	Nucleocapsid Dimensions, Symmetry diameter = 29.8 +- 2.5 nm
--	--	---

Morphogenesis

Site of Constituent Formation in Cell	Site of Virion Assembly cytoplasm (41)	Site of Virion Accumulation cytoplasm vacuolium (41)
---------------------------------------	--	--

Inclusion Bodies not observed	Other
---	-------

Hemagglutination

Hemagglutination Yes	Antigen Source SMB ext. by borate-KCl, pH 9.0; acetone-ether; sucrose-acetone (17)	Erythrocytes (species used) goose
--------------------------------	--	---

pH Range 6.0 - 7.2	pH Optimum 6.6
------------------------------	--------------------------

Temperature Range 4-37dC	Temperature Optimum 25dC
------------------------------------	------------------------------------

Remarks

Serologic Methods Recommended
HI, CF, NT

Footnotes

Section V - Antigenic Relationship and Lack of Relationship to Other Viruses

Related antigenically to other flaviviruses (group B) especially West Nile, Murray Valley and Saint Louis encephalitis viruses. See reference [46].

Section VI - Biologic Characteristics

Virus Source (all VERTEBRATE isolates)
blood (M)(LV), CSF (M), CNS (M)(LV), heart (LV), lung (LV),
liver (LV), spleen (LV), kidney (LV). Present in most organs of
lower vertebrates during viremia.

Lab Methods of Virus Recovery (ALL ISOLATIONS)
newborn and weaning mice, primary chick embryo cell
cultures and C6/36 clone of Aedes albopictus cells.

Cell system (a)	Virus passage history (b)	Evidence of Infection						
		CPE			PLAQUES			Growth Without CPE +/- (g)
		Day (c)	Extent (d)	Titer TCD50/ml (e)	Day (c)	Size (f)	Titer PFU/ml (e)	
chick embryo (PC), human epithelial (CL), L mouse cells			Minimal CPE		5-7	Plaques		+
Vero (CL)	P-52				4	3mm	9.1* (28)	
LLC-MK2 (CL)					3	8mm	9.4 (28)	
C6/36 (CL)			CPE			Plaques (40)		
PS (CL)	P-43	3	4+	8.0*	3-4	5-6mm	8.3 (45)	

* Expressed in dex

Vertebrate (species and organ) and arthropod	No. isolations/No. tested	No. with antibody/No. tested Test used	Country and region	
Man	numerous	Reported anti-body prevalences are low	Eastern Asia from Japan to, India (11)	
Horses	numerous			
Pigs	numerous			
Wild birds-chiefly herons and egrets (7-10)	numerous			
Other domestic animals				
Wild rodents				
Cx tritaeniorhynchus	3			Java (33)
Culex tritaeniorhynchus	numerous			Northeastern Asia
Culex pipiens	rare			North and, SE Asia
Culex gelidus	some			SE Asia
Culex annulus	2	Taiwan (31)		
Culex fuscocephala	some	Thailand (39)		
Poikilothermic hosts	poss. isol.	Korea and, Taiwan (27)		
Bats:				
Hipposideros a. terasensis	1		Taiwan (31)	
Miniopterus s. fuliginosus	2			
Culex vishnui	2		W. Bengal, India (32)	
Anopheles barbirostris	1			
An hyrcanus	1			

In man, horses, and pigs, inapparent infection is the rule. Antibody prevalences range up to 90-100%.

Experimental host and age	Passage history and strain	Inoculation Route-Dose	Evidence of infection	AST (days)	Titer log ₁₀ /ml
mice (nb)		ic 0.01	Encephalitis and death	3-4	8-9
mice (nb)		ip 0.01	Encephalitis and death	4-5	8-9
mice (nb)		sc			
mice (wn)		ic 0.03	Encephalitis and death	5-6	7-8
mice (wn)	certain strains only	ip 0.2	Encephalitis and death	6-10	1-9
monkeys, rhesus and cynmolgus	mosquitoes or low mouse	peripheral	Asymptomatic viremia		
hamsters		ic	Encephalitis and death		
hamsters		peripheral	Asymptomatic viremia		
guinea pigs		ic or peripheral	Asymptomatic viremia; antibody		
rabbits		ic or peripheral	Asymptomatic viremia; antibody		
chickens, herons and some other birds		peripheral	Asymptomatic viremia; antibody		
horses		ic or peripheral	Encephalitis with some strains		
pigs - not pregnant		peripheral	Asymptomatic viremia; antibody		
pigs - pregnant		peripheral	Birth, sometimes premature, of infected often dead fetuses		
bats		peripheral	Asymptomatic viremia		
embryonated egg		ys, other routes	Death		

Rats, toads, frogs and snakes circulate virus (18, 38)

Dogs, foxes, cats, and goats undergo paralysis and death after ic or iv inoculation (13-16)

Arthropod species & virus source(a)	Method of Infection log10/ml (b)		Incubation period (c)		Transmission by bite (d)		Assay of arthropod, log10/ml (e)		
	Feeding	Injected	Days	°C	Host	Ratio	Whole	Organ	System
<i>Culex tritaeniorhynchus</i>									
Viremic pig (19)	4.7		15-29	23-25	chicken	92			
Viremic chicken (19,200)	3.6-4.0		10-34	23-25	chicken	46	3.0-5.7		weanling mice ic
<i>Culex fuscocephalus</i>									
Viremic pig (42)	3.6		17-18	28	chicken	40			
Viremic chicken (43)	3.9		10-27	25-27	chicken	16			
<i>Culex gelidus</i>									
Viremic chicken (23)	4.0-4.9		6-21+	27	chicken	50			
Viremic chicken (23)	5.1		21	27			6.2-6.9		weanling mice ic

Transovarial transmission demonstrated in *Aedes albopictus*, *Ae togoi* (44). Successfully infected adults of *Culex quinquefasciatus*, *Cx. Jepson*: (= *Cx (Cux sitiens)*) (larvae as well) and *Ae vexans*; JBE transmitted to SM by bite (47).

Section X - Histopathology

Character of lesions (specify host)

acute encephalitis

Inclusion Bodies

Intranuclear

Organs/Tissues Affected

brain (M) (LV)

Category of tropism

neurotropic, encephalitis

Section XI - Human Disease

In Nature Significant	Residual Significant	Death Significant
Subclinical Reported	Overt Disease Reported	
Clinical Manifestations fever (S), headache (S), prostration (S), stiff neck (R), CNS signs including encephalitis (S), CNS pleocytosis (S)		
Number of Cases thousands	Category (i.e. febrile illness, etc.) encephalitis	

Section XII - Geographic Distribution

Known (Virus detected)
Suspected (Antibody only detected) Viet Nam, Burma

1. Mitamura, T., et al. 1935. *Kansai Iji* 260-261:1-5.
2. Mitamura, T., et al. 1936. *Trans. Soc. Path. Jap.* 26:429-452.
3. Mitamura, T., et al. 1938. *Tokyo Ijishinshi* 3076:766-777.
4. Mitamura, T., et al. 1936. *Ibid.* 3006:3149-3156.
5. Mitamura, T., et al. 1936. *Ibid.* 3006:3157-3161.
6. Mitamura, T., et al. 1938. *Ibid.* 3076:771-773.
7. Mitamura, T., et al. 1937. *Trans. Soc. Path. Jap.* 27:573-580.
8. Mitamura, T., et al. 1938. *Ibid.* 28:135-145.
9. Mitamura, T., et al. 1939. *Ibid.* 29:92-105.
10. Mitamura, T., et al. 1940. *Ibid.* 30:561-570.
11. Mitamura, T., et al. 1938. *Tokyo Ijishinshi* 3076:779-789.
12. Mitamura, T., et al. 1936. *Tokyo Ijishinshi* 3006:3162-3169.
13. Mitamura, T., et al. 1936. *Ibid.* 3006:3170-3172.
14. Mitamura, T., et al. 1937. *Ibid.* 3030:1145-1155.
15. Mitamura, T., et al. 1938. *Ibid.* 3030:778-779.
16. Mitamura, T., et al. 1938. *Ibid.* 3079:1097-1139.
17. Clarke, D.H. and Casals, J. 1958. *Am. J. Trop. Med. Hyg.* 7:561-573.
18. Kitaoka, M. Unpublished observation.
19. Gresser, I., et al. 1958. *Am. J. Trop. Med. Hyg.* 7:365-373.
20. Gresser, I., et al. 1958. *Jap. J. Trop. Med.* 28:243-248.
21. Buescher, E.L., et al. 1959. *J. Immunol.* 83:582-626.
22. Buescher, E.L., et al. 1962. *Am. J. Vet. Res.* 23:1157-1163.
23. Gould, D.J., et al. 1962. *Trans. Roy. Soc. Trop. Med. Hyg.* 56:429-435.
24. Scherer, W.F., et al. 1959. *Am. J. Trop. Med. Hyg.* 8:644-722.
25. Rivers, T.M. and Horsfall, F.L. 1959. *Viral and Rickettsial Infections of Man.* 3rd Ed. pp. 312-319.
26. Theiler, M. 1957. *Proc. Soc. Exp. Biol. Med.* 96:380-382.
27. Lee, H.W. 1971. *J. Korean Med. Assoc.* 14:871-878.
28. Stim, T.B. 1969. *J. Gen. Virol.* 5:329-338.
29. Karpova, E.F., et al. 1972. *Vop. Virusol.* 17:207-210.
30. Simasathien, P., et al. 1972. *SE Asian J. Trop. Med. Publ. Health* 3:52.
31. Cross, J.H., et al. 1971. *J. Formosan Med. Assoc.* 70:681-686.
32. Sarkar, J.K. Personal communication. 1973.
33. Van Peenen, P.F.D., et al. 1974. *Milit. Med.* 139:821-823.
34. Rosen, L., et al. 1978. *Science* 199:909-911.
35. Kitano, T., et al. 1974. *J. Virol.* 14:631-639.
36. Shapiro, D., et al. 1971. *Virology* 44:108-124.
37. Trent, D.W. 1977. *J. Virol.* 22:608-618.
38. Shortridge, K.F., et al. 1977. *Trans. Roy. Soc. Trop. Med. Hyg.* 71:261-262.
39. Gould, D.J., et al. 1974. *Am. J. Epidem.* 100:49-56.
40. Igarashi, A. Personal communication.
41. Ota, Z. 1965. *Virology* 25:372-378.
42. Okuno, T., et al. 1975. *Ann. Trop. Med. Parasitol.* 69:203-206.
43. Muangman, D., et al. 1972. *Am. J. Trop. Med. Hyg.* 21:482-486.
44. Rosen, L., et al. 1978. *Science* 199:909-911.
45. Westaway, E.G. 1966. *Am. J. Epidem.* 84:439-456.
46. De Madrid, A.T. and Porterfield, J.S. 1974. *J. Gen Virol.* 23:91-96.
47. Hodes, H.L. and Hurlburt, H.S.; 1946. *Am. J. Dis. Child.* 72:464.

Remarks

In Japan, ecologic cycle involves vectors (*Culex tritaeniorhynchus*), available amplifier hosts (pigs, herons, egrets and other birds) and diseased hosts (man, horses and pregnant pigs).